Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668968 | 0.75 | CNR2 (0.32) | POLBHTTMEN1KMT2AMAPT | |
| SCHEMBL319961 | 0.74 | SMN1; SMN2 (0.38) | ABL1 | |
| SCHEMBL9196435 | 0.69 | MAPK1 (0.32) | — | |
| SCHEMBL9210244 | 0.69 | HDAC3 (0.35) | HTTMEN1KMT2AMAPT | |
| SCHEMBL27737090 | 0.67 | ABCB1 (0.32) | — | |
| SCHEMBL326998 | 0.66 | PIK3CD (0.33) | HTTMAPT | |
| SCHEMBL27767920 | 0.65 | POLB (0.43) | ALPLPOLBAPEX1HTTANO1 | |
| SCHEMBL27768015 | 0.65 | POLB (0.43) | ALPLPOLBAPEX1HTTANO1 | |
| SCHEMBL12806428 | 0.65 | L3MBTL1 (0.47) | MEN1KMT2AMAPT | |
| SCHEMBL1745697 | 0.63 | SLC1A3 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| EP-3043787-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORP (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-2968234-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORP (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3193610-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | Chromocell Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160221974-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3043787-A2 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | Chromocell Corporation (US) | 2016-07-20 | — | — | EP | disclosed |
| WO-2016040315-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2968234-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Chromocell Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151472-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221974-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | SCN7A, SCN1A, SCN10A | ALPL 3270/4885POLB 4699/4885APEX1 4782/4885 |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | SCN7A, SCN10A, SCN2A | ALPL 3132/4885POLB 4644/4885APEX1 4717/4885 |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | SCN7A, SCN10A, SCN2A | ALPL 3132/4885POLB 4644/4885APEX1 4717/4885 |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | SCN7A, SCN1A, SCN1B | ALPL 2245/4885POLB 3876/4885APEX1 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.